GPS Wealth Strategies Group LLC Decreases Stake in GSK plc (NYSE:GSK)

GPS Wealth Strategies Group LLC cut its holdings in shares of GSK plc (NYSE:GSK) by 11.0% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 2,425 shares of the pharmaceutical company’s stock after selling 300 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in GSK were worth $93,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Register Financial Advisors LLC bought a new position in GSK in the first quarter valued at about $31,000. Richardson Financial Services Inc. bought a new position in shares of GSK in the 4th quarter worth approximately $40,000. Newbridge Financial Services Group Inc. bought a new position in shares of GSK in the 1st quarter worth approximately $49,000. Jones Financial Companies Lllp boosted its holdings in shares of GSK by 23.1% in the fourth quarter. Jones Financial Companies Lllp now owns 1,633 shares of the pharmaceutical company’s stock worth $61,000 after buying an additional 306 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new stake in GSK during the first quarter valued at approximately $62,000. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK traded up $0.03 during trading hours on Wednesday, hitting $41.21. The company’s stock had a trading volume of 2,482,776 shares, compared to its average volume of 3,595,126. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92. The stock has a market cap of $85.41 billion, a price-to-earnings ratio of 14.89, a P/E/G ratio of 1.32 and a beta of 0.64. The business’s 50-day moving average price is $39.75 and its 200-day moving average price is $41.44. The company has a current ratio of 0.82, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be given a $0.3843 dividend. The ex-dividend date is Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 3.73%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 54.71%.

Analyst Ratings Changes

Several research firms have weighed in on GSK. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. The Goldman Sachs Group assumed coverage on GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price target for the company. Citigroup raised GSK to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.